Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Biochemical and clinical parameters at baseline and at the end of the study (n 36)(Median values and interquartile ranges (IQR))Fish group (n 12)‡Control group (n 12)Krill group (n 12)§BaselineEnd of studyBaselineEnd of studyBaselineEnd of studyMedianIQRMedianIQRMedianIQRMedianIQRMedianIQRMedianIQRPǁTotal cholesterol (mmol/l)5·80·95·91·25·71·26·01·36·21·36·31·30·590HDL-cholesterol (mmol/l)1·40·31·30·31·30·41·30·31·40·21·40·30·674LDL-cholesterol (mmol/l)3·90·93·70·93·82·04·21·54·01·03·90·90·700ApoA1 (g/l)1·80·21·70·11·80·51·60·21·60·31·70·20·255ApoB (g/l)1·20·21·10·31·20·41·20·41·30·31·30·30·212ApoB/ApoA10·70·20·70·30·70·30·70·20·80·10·80·10·866Lp(a) (mg/l)106129113109133139124133100101100640·974BMI (kg/m2)28·55·528·75·328·05·027·75·126·45·126·15·40·046†Systolic BP (mmHg)1271712326122281322112211126200·362Diastolic BP (mmHg)82127519781278137698080·356hsCRP (mg/l)1·30·81·41·01·32·61·32·41·32·01·92·60·168Vitamin D (nmol/l)5626723172337814763067160·024*HbA1c (%)5·70·55·60·55·40·35·40·05·40·25·40·20·673Glucose (mmol/l)5·30·55·40·55·20·35·50·45·60·65·30·50·024†TSH (mU/l)2·01·31·51·11·70·72·01·21·31·01·51·00·193Free T4 (pmol/l)15·14·016·02·615·13·515·83·516·32·716·91·40·589Free T3 (pmol/l)5·30·75·10·44·90·45·10·45·20·85·10·50·144Creatinine (μmol/l)6717691381197820741572170·761eGFR (ml/min per 1·73 m2)9316942082218716911989200·891ALAT (U/l)29172872572013221022150·303γ-GT (U/l)31273027247219241325490·014†Lp(a), lipoprotein a; BP, blood pressure; hsCRP, high-sensitivity C-reactive protein; HbA1c, glycosylated Hb; TSH, thyroid-stimulating hormone; T4, thyroxine; T3, triiodothyronine; eGFR, estimated glomerular filtration rate; ALAT, alanine aminotransferase; γ-GT, γ-glutamyl transferase.Significantly different between the fish group and krill group (P < 0·05).Significantly different between the krill group and control group (P < 0·05).n 11 for apoA1, apoB, Lp(a), HbA1c, glucose, vitamin D, creatinine, ALAT and γ-GT. n 9 for eGFR.n 11 for HbA1c and ALAT.Overall difference between the three intervention groups was tested with the Kruskal: Wallis test; P values are given in the Table.
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Effects of krill oil and lean and fatty fish on cardiovascular risk markers: a randomised controlled trial
Source: Article title.
Healthy men and women aged 18 to 70 years living in the Skedsmo municipality, Akershus county, Norway were recruited by invitation by post using addresses extracted from the National Registry with permission from the Directorate of Taxes.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effects of krill oil and lean and fatty fish on cardiovascular risk markers: a randomised controlled trial
Randomised controlled trial · Journal of Nutritional Science · 2018
Original publication title
Effects of krill oil and lean and fatty fish on cardiovascular risk markers: a randomised controlled trial
© The Author(s) 2018
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Fish consumption and supplementation with n-3 fatty acids reduce CVD risk. Krill oil is an alternative source of marine n-3 fatty acids and few studies have investigated its health effects. Thus, we compared krill oil supplementation with the intake of fish with similar amounts of n-3 fatty acids on different cardiovascular risk markers. In an 8-week randomised parallel study, thirty-six healthy subjects aged 18 to 70 years with fasting serum TAG between 1·3 and 4·0 mmol/l were randomised to receive either fish, krill oil or control oil.
In the fish group, subjects consumed lean and fatty fish, according to dietary guidelines. The krill and control group received eight capsules per d containing 4 g oil per d. The weekly intake of marine n-3 fatty acids from fish given in the fish group and from krill oil in the krill group were 4103 and 4654 mg, respectively. Fasting serum TAG did not change between the groups. The level of total lipids (P = 0·007), phospholipids (P = 0·015), cholesterol (P = 0·009), cholesteryl esters (P = 0·022) and non-esterified cholesterol (P = 0·002) in the smallest VLDL subclass increased significantly in response to krill oil supplementation.
Blood glucose decreased significantly (P = 0·024) in the krill group and vitamin D increased significantly in the fish group (P = 0·024). Furthermore, plasma levels of marine n-3 fatty acids increased significantly in the fish and krill groups compared with the control (all P ≤ 0·0003). In conclusion, supplementation with krill oil and intake of fish result in health-beneficial effects. Although only krill oil reduced fasting glucose, fish provide health-beneficial nutrients, including vitamin D.
Authors’ abstract
Fish consumption and supplementation with n-3 fatty acids reduce CVD risk. Krill oil is an alternative source of marine n-3 fatty acids and few studies have investigated its health effects. Thus, we compared krill oil supplementation with the intake of fish with similar amounts of n-3 fatty acids on different cardiovascular risk markers. In an 8-week randomised parallel study, thirty-six healthy subjects aged 18 to 70 years with fasting serum TAG between 1·3 and 4·0 mmol/l were randomised to receive either fish, krill oil or control oil.
In the fish group, subjects consumed lean and fatty fish, according to dietary guidelines. The krill and control group received eight capsules per d containing 4 g oil per d. The weekly intake of marine n-3 fatty acids from fish given in the fish group and from krill oil in the krill group were 4103 and 4654 mg, respectively. Fasting serum TAG did not change between the groups. The level of total lipids (P = 0·007), phospholipids (P = 0·015), cholesterol (P = 0·009), cholesteryl esters (P = 0·022) and non-esterified cholesterol (P = 0·002) in the smallest VLDL subclass increased significantly in response to krill oil supplementation.
Blood glucose decreased significantly (P = 0·024) in the krill group and vitamin D increased significantly in the fish group (P = 0·024). Furthermore, plasma levels of marine n-3 fatty acids increased significantly in the fish and krill groups compared with the control (all P ≤ 0·0003). In conclusion, supplementation with krill oil and intake of fish result in health-beneficial effects. Although only krill oil reduced fasting glucose, fish provide health-beneficial nutrients, including vitamin D.
Publication and source details
Original title: Effects of krill oil and lean and fatty fish on cardiovascular risk markers: a randomised controlled trial
Amanda Rundblad; Kirsten B. Holven; Inge Bruheim; Mari C. Myhrstad; Stine M. Ulven
Journal of Nutritional Science · 2018
* Corresponding author: S. M. Ulven, email smulven@medisin.uio.noCurrent address: Møreforsking Ålesund, Postboks 5075, Larsgården, 6021 Ålesund, Norway.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T22:05:58.020535+00:00
DOI: 10.1017/jns.2017.64 · PMC5773922